Details of the Drug Reposition

General Information of This Drug (ID: DMDS20X)

Drug Name	Enoblituzumab DMDS20X

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 2	[1]
Prostate cancer	DISF190Y	2C82.0	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02923180) Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer. U.S. National Institutes of Health.